AntagomiR oligonucleotides to treat Myotonic Dystrophy patients.
Arthex Biotech has raised €78M across 4 funding rounds from 11 investors. Based in Valencia, Spain; founded 2019; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
